Search Results
You are looking at 1 - 1 of 1 items for
- Author: Mi Yeon Lee x
- Refine by access: Content accessible to me x
Search for other papers by Yeon A Choi in
Google Scholar
PubMed
Search for other papers by Ja Seung Koo in
Google Scholar
PubMed
Search for other papers by Jeong Su Park in
Google Scholar
PubMed
Search for other papers by Mi Young Park in
Google Scholar
PubMed
Search for other papers by Ae Lee Jeong in
Google Scholar
PubMed
Search for other papers by Ki-Sook Oh in
Google Scholar
PubMed
Search for other papers by Young Yang in
Google Scholar
PubMed
Cancerous inhibitor of PP2A (CIP2A) stimulates the proliferation of various cancer cells, and 17β-estradiol (E2) enhances the proliferation of breast cancer cells. E2 activates epidermal growth factor receptor (EGFR), stimulating the MEK1/2 and PI3K pathways, and CIP2A expression is increased by the MEK1/2-induced transcription factor ETS1. It is possible for E2 to increase CIP2A expression. This study examined whether E2 could increase CIP2A expression and whether CIP2A is highly expressed in estrogen receptor (ER)-positive breast cancer tissues. E2 increased CIP2A expression at the translational level in a c-MYC-independent manner in MCF-7 cells. E2-enhanced proliferation was impaired without CIP2A expression. E2-stimulated EGFR activated the MAPK and PI3K pathways, which converged to activate p70 S6 kinase (S6K). Phosphorylation at all the three phosphorylation sites (S424/T421, T229, and T389) on S6K was required for the phosphorylation of eukaryotic initiation factor 4B (eIF4B), which was responsible for the increase in CIP2A translation. Furthermore, CIP2A expression was higher in ER-positive tissues than in ER-negative tissues. This is the first study, to our knowledge, to demonstrate that CIP2A is a key factor in E2-enhanced proliferation and that estrogen regulates CIP2A expression by non-genomic action through EGFR.
